A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

Hepatitis C Virus: ADVANCE Clinical Trial Data Provides New Details Regarding Telaprevir’s Clinical Profile

Based on our Pharmacor advisory service entitled Hepatitis C Virus, Decision Resources is offering an exclusive analyst call entitled Hepatitis C Virus: ADVANCE Clinical Trial Data Provides New Details Regarding Telaprevir’s Clinical Profile. Because this presentation will feature updates to the Hepatitis C Virus topic, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Vertex Pharmaceuticals recently announced results from the first Phase III clinical trial of telaprevir–the global ADVANCE study conducted in hepatitis C virus (HCV) genotype 1 treatment-naive patients. The data revealed by Vertex is in line with Decision Resources’ previously reported expectations for telaprevir to become the first-to-market HCV-specific antiviral agent in 2011. However, the clinical trial results also provided additional information regarding the safety and efficacy of this protease inhibitor.

This 15-minute analyst call, presented by Alexandra Makarova, M.D., Ph.D., will answer the following questions:

How can the ADVANCE trial data be compared with earlier telaprevir trials and do the results of the trial affect Decision Resources’ view of the efficacy-safety balance of telaprevir?
What effect will the recent trial results have on the likelihood of telaprevir to fulfill clinicians’ expectations for novel HCV-specific antiviral agents?
How does 100 percent follow up and strict adherence to the ADVANCE trial protocol affect the interpretation of the top line results?

Dr. Makarova will conduct a live Q & A session after the presentation.

Registration

Hepatitis C Virus: ADVANCE Clinical Trial Data Provides New Details Regarding Telaprevir’s Clinical Profile

June 11, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Friday, June 11, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Alexandra Makarova, M.D., Ph.D., is a research analyst at Decision Resources, specializing in infectious disease. Prior to joining the company, Dr. Makarova completed a postdoctoral fellowship at the Mass General Institute for Neurodegenerative Disease (Harvard Medical School). Dr. Makarova is an author of several peer-reviewed research articles. She holds a Ph.D. in neuroscience from George Washington University and an M.D. with specialization in medical biochemistry from Russian State Medical University.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.